We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




BRIC Countries Outperform Rest of the World in IVD Sales Growth

By LabMedica International staff writers
Posted on 27 Jun 2011
The rate of growth for diagnostic instrumentation, product, and reagent sales for Brazil, Russia, India, and China (dubbed the BRIC nations) is double the six percent growth rate projected for worldwide in vitro diagnostics (IVD) sales.

In BRIC nations IVD sales are expected to grow from US $2.9 billion in 2009 to $5 billion in 2014, which represents a compound annual growth rate (CAGR) of 12%. More...
The market in these countries is dominated by companies such as Roche (Basel, Switzerland), Abbott (Des Plaines, IL, USA), Siemens (Munich, Germany), and Beckman Coulter (Fullerton, CA, USA). Domestic companies such as Transasia (Mumbai, India), Horiba (Kyoto, Japan), and Mindray (Shenzhen, China) have taken the distribution of IVD products from urban areas to the rural areas in their respective markets. Incumbent companies tend to provide a host of routine tests.

It is expected that as the IVD demand in developing countries increases, there will be opportunities for rapid tests and advanced tests that are now emerging as local healthcare systems become more sophisticated.

A report from Kalorama Information (Rockville, MD, USA), publisher of research in medical markets, presents the challenges that BRIC countries face entering the IVD market. The report also explores the opportunities that specific developing countries offer to IVD companies. Kalorama attempts to add some realistic aspects of working in a foreign country that are more qualitative in nature.

A number of reports on the BRIC and emerging markets have been published. Most of these focus on quantitative data such as number of labs, hospitals, product registration regulations, and import taxes and conditions. Too many of them tend to present only a growth scenario without presenting the challenges the nations face.

Some of the same trends–growing middle class, mix of infectious and noncommunicable diseases, and government supported healthcare–are prevalent in many countries in Eastern Europe and Africa. Kalorama provides three non-BRIC nations: Turkey, Poland, and Nigeria as examples of where IVD may flourish in the future.

Author of the report, Shara Rosen, RT, MBA, commented, "It is now recognized that it's the low- and middle-income countries that face the greatest burden of chronic diseases such as diabetes, heart disease, and cancer. As markets in industrialized countries begin to mature, IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and a growing demand for quality medical care."

Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare, as well as a full range of custom research services.

Related Links:

Kalorama Information


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
Clinical Chemistry System
P780
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.